Stock Mover of The Day: Vitae Pharmaceuticals Q2 2016 Institutional Investor Sentiment Better Than Expected

November 15, 2016 - By Marguerite Chambers   ·   0 Comments

Stock Mover of The Day: Vitae Pharmaceuticals  Q2 2016 Institutional Investor Sentiment  Better Than Expected

Sentiment for Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals (NASDAQ:VTAE) institutional sentiment increased to 1.92 in Q2 2016. Its up 0.56, from 1.36 in 2016Q1. The ratio has improved, as 48 hedge funds started new and increased stock positions, while 25 reduced and sold stock positions in Vitae Pharmaceuticals. The hedge funds in our partner’s database reported: 20.80 million shares, up from 19.72 million shares in 2016Q1. Also, the number of hedge funds holding Vitae Pharmaceuticals in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 14 Reduced: 11 Increased: 37 New Position: 11.

Vitae Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $605.95 million. The Firm is focused on discovering and developing small molecule drugs for diseases. It currently has negative earnings. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform.

It is down 212.04% since March 23, 2016 and is uptrending. It has outperformed by 208.11% the S&P500.

Dafna Capital Management Llc holds 5.65% of its portfolio in Vitae Pharmaceuticals Inc for 660,188 shares. Awm Investment Company Inc. owns 1.18 million shares or 2.72% of their US portfolio. Moreover, Cormorant Asset Management Llc has 2.68% invested in the company for 1.75 million shares. The Massachusetts-based Ra Capital Management Llc has invested 2.35% in the stock. Bvf Inc Il, a California-based fund reported 761,079 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 2 insider sales for $22.41 million net activity.

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Ratings Coverage

Ratings analysis reveals 40% of Vitae Pharmaceuticals’s analysts are positive. Out of 5 Wall Street analysts rating Vitae Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. VTAE was included in 7 notes of analysts from August 8, 2015. The firm has “Market Perform” rating given on Thursday, September 15 by Wells Fargo. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) has “Outperform” rating given on Friday, December 4 by Wells Fargo. BMO Capital Markets initiated Vitae Pharmaceuticals Inc (NASDAQ:VTAE) on Tuesday, April 12 with “Outperform” rating. The stock has “Market Perform” rating given by JMP Securities on Thursday, August 4. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) earned “Buy” rating by Stifel Nicolaus on Thursday, March 17. As per Saturday, August 8, the company rating was upgraded by Zacks. Piper Jaffray downgraded Vitae Pharmaceuticals Inc (NASDAQ:VTAE) on Wednesday, September 21 to “Neutral” rating.

More important recent Vitae Pharmaceuticals Inc (NASDAQ:VTAE) news were published by: which released: “Here’s Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today” on September 14, 2016, also published article titled: “Vitae Pharma Prepares for Secondary Offering”, published: “Could This Be the Big Comeback for Vitae Pharma?” on March 17, 2016. More interesting news about Vitae Pharmaceuticals Inc (NASDAQ:VTAE) was released by: and their article: “Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 …” with publication date: November 18, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News